Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives $56.35 Average Target Price from Brokerages

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) has been given an average recommendation of “Moderate Buy” by the eight analysts that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $56.35.

A number of research analysts recently issued reports on ZLAB shares. Citigroup reiterated a “buy” rating and set a $69.00 price objective (up from $66.00) on shares of Zai Lab in a research note on Monday, August 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zai Lab in a report on Wednesday, October 8th. Finally, Jefferies Financial Group started coverage on shares of Zai Lab in a research report on Monday, August 25th. They issued a “buy” rating and a $52.00 price target for the company.

Zai Lab Price Performance

Shares of Zai Lab stock opened at $20.42 on Thursday. The stock has a market capitalization of $2.28 billion, a PE ratio of -10.01 and a beta of 1.07. Zai Lab has a 1-year low of $19.51 and a 1-year high of $44.34. The company’s fifty day simple moving average is $26.88 and its 200-day simple moving average is $31.97.

Zai Lab (NASDAQ:ZLAB) last released its earnings results on Thursday, November 6th. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.05). The company had revenue of $116.10 million for the quarter, compared to analysts’ expectations of $150.24 million. Zai Lab had a negative net margin of 49.68% and a negative return on equity of 27.32%. Zai Lab has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that Zai Lab will post -2.58 EPS for the current year.

Insider Transactions at Zai Lab

In other Zai Lab news, insider Joshua L. Smiley purchased 10,000 shares of the business’s stock in a transaction on Wednesday, September 10th. The stock was acquired at an average price of $28.91 per share, for a total transaction of $289,100.00. Following the purchase, the insider owned 86,604 shares of the company’s stock, valued at approximately $2,503,721.64. This represents a 13.05% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 4.96% of the company’s stock.

Hedge Funds Weigh In On Zai Lab

A number of hedge funds have recently made changes to their positions in ZLAB. Walleye Capital LLC raised its stake in Zai Lab by 6.4% during the 1st quarter. Walleye Capital LLC now owns 22,276 shares of the company’s stock valued at $805,000 after purchasing an additional 1,338 shares during the period. Caitong International Asset Management Co. Ltd bought a new stake in shares of Zai Lab during the first quarter valued at approximately $75,000. Hsbc Holdings PLC lifted its holdings in shares of Zai Lab by 32.7% in the first quarter. Hsbc Holdings PLC now owns 25,000 shares of the company’s stock worth $894,000 after buying an additional 6,160 shares in the last quarter. Avantax Advisory Services Inc. bought a new position in shares of Zai Lab during the first quarter worth $225,000. Finally, ABC Arbitrage SA bought a new position in shares of Zai Lab during the first quarter worth $225,000. Institutional investors own 41.65% of the company’s stock.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.